Lyell Immunopharma

Lyell Immunopharma is a cellular therapy company focused on developing curative cell-based immunotherapies for solid tumors. Based in South San Francisco, the company's mission is to reprogram T cells to effectively combat cancer. Lyell's approach addresses major barriers to effective cell therapy in solid tumors, utilizing innovative technologies to enhance the efficacy of immunotherapies.

The company's multi-modal product pipeline targets solid tumor cancers with significant unmet medical needs. Founded by Rick Klausner, M.D., Lyell Immunopharma aims to conquer what they consider oncology's unfinished business: creating curative cell therapies for solid tumors. Their work represents a promising frontier in cancer treatment, potentially offering new hope for patients with challenging-to-treat solid tumor cancers.